Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
Department of Developmental Therapy Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
J Am Acad Dermatol. 2017 Sep;77(3):489-496. doi: 10.1016/j.jaad.2017.05.015. Epub 2017 Jul 1.
The prognosis of the CD8 subtype of mycosis fungoides (MF) is controversial. Although most authors believe that determining the presence of this cell surface antigen has no prognostic value, others have observed a more indolent course for CD8 MF compared with CD4 MF.
To review the cases of CD8 MF in the pediatric and adult populations seen at our institution.
This is a retrospective review of clinical and pathologic data. Age, stage at presentation, and outcomes of patients at our institution were compared with those of 2 large MF cohorts that predominantly were CD4 from the relevant literature.
Sixty-seven patients of a median age of 46 years were included. A higher frequency of early-stage disease was observed for CD8 MF patients at diagnosis when compared with other cohorts, including 31 (47%) patients with stage IA, 33 (50%) with stage IB, and 2 (3%) with stage IIB (P = .001, P = .001, and P = .002, respectively). With a median follow-up (5.5 years, range 0.2-21 years) similar to other cohorts, a higher rate of complete remission was achieved (65.5%, P = .001), and a lower rate of progression was observed (P = .004).
This is a retrospective review.
Our experience with CD8 MF confirms a more indolent course of disease with this MF variant. Our results warrant a conservative treatment approach limited to skin-directed therapies and observation in most patients.
蕈样肉芽肿（MF）CD8 亚型的预后存在争议。尽管大多数作者认为确定这种细胞表面抗原的存在没有预后价值，但也有作者观察到 CD8 MF 比 CD4 MF 具有更惰性的病程。
回顾本机构所见儿童和成人 CD8 MF 的病例。
这是一项回顾性的临床和病理数据分析。比较了本机构患者的年龄、发病时的分期以及转归，与来自相关文献的 2 个主要为 CD4 的 MF 队列的结果。
纳入了 67 例中位年龄为 46 岁的患者。与其他队列相比，CD8 MF 患者在诊断时更常处于早期疾病阶段，包括 31 例（47%）IA 期、33 例（50%）IB 期和 2 例（3%）IIB 期（P=0.001，P=0.001 和 P=0.002）。中位随访时间（5.5 年，范围 0.2-21 年）与其他队列相似，完全缓解率更高（65.5%，P=0.001），进展率较低（P=0.004）。
这是一项回顾性研究。
我们对 CD8 MF 的经验证实了这种 MF 变体具有更惰性的病程。我们的结果证明，在大多数患者中，采用仅限于皮肤靶向治疗和观察的保守治疗方法是合理的。
